Use and misuse of triptans in France: Data from the GRIM2000 population survey

Cephalalgia

Volumn 24, Issue 3, 2004, Pages 197-205

  Lucas, C ^a   Auray, J P ^b   Gaudin, A F ^c   Dartigues, J F ^d   Duru, G ^b   Henry, P ^e   Lanteri Minet M ^f   Pradalier, A ^g   Chazot, G ^h   El Hasnaoui, A ^c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c GLAXOSMITHKLINE   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e HÔPITAL PELLEGRIN   (France)

^f PASTEUR HOSPITAL   (France)

^g HÔPITAL LOUIS MOURIER   (France)

^h HÔPITAL NEUROLOGIQUE   (France)

Author keywords

Epidemiology; France; Headache; Migraine; Triptans

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; NARATRIPTAN; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN;

ADULT; CONSUMER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MISUSE; DRUG USE; DRUG UTILIZATION; FEMALE; FRANCE; HEADACHE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PRESCRIPTION; REVIEW; SEX DIFFERENCE;

EID: 12144289901     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2003.00651.x     Document Type: Review

References (25)

1. Bateman DN. Triptans and migraine. Lancet 2000; 335:860-1.
2. Saxena PR. Serotonin receptors: subtypes, functional responses and therapeutic relevance. Pharmacol Ther 1995; 66:339-68.
3. 1B/1D receptor agonists in migraine. Comparative pharmacology and its therapeutic implications. CNS Drugs 1998; 10:271-86.
4. Wilkinson M, Pfaffenrath V, Schoenen J, Diener HC, Steiner TJ. Migraine and cluster headache - their management with sumatriptan: a critical review of the current clinical experience. Cephalalgia 1995; 15:337-57.
5. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000; 60:1259-87.
6. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358:1668-75.
7. Gaist D. Use and overuse of sumatriptan. Pharmacoepidemiological studies based on prescription register and interview data. Cephalalgia 1999; 19:735-61.
8. Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia 1992; 12:221-8.
9. Henry P, Auray JP, Gaudin AF, Dartigues JF, Duru G, Lantéri-Minet M et al. Prevalence and clinical characteristics of migraine in France. Neurology 2002; 59:232-7.
10. Richard A, Henry P, Chazot G, Massiou H, Tison S, Marconnet R et al. Qualité de vie et migraine. Validation du questionnaire QVM en consultation hospitalière et en médecine générale. Therapie 1993; 48:89-96.
11. Lipton RB, Stewart WF, Edmeads JG, Sawyer J. Clinical utility of a new instrument assessing migraine disability: the migraine disability assessment score (MIDAS). Headache 1998; 38:390-1.
12. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 1988; 8 (Suppl. 7):1-96.
13. Michel P, Dartigues JF, Henry P, Tison S, Auriacombe S, Brochet B et al. Validity of the International Headache Society criteria for migraine. Neuropepidemiology 1993; 12:51-7.
14. Lantéri-Minet M, Auray JP, El Hasnaoui A, Dartigues JF, Duru G, Henry P, et al. Prevalence and description of chronic daily headache in the general population in France. Pain 2003; 102:143-9.
15. Pradallier A, Auray JP, El Hasnaoui A, Alzahouri K, Dartigues JF, Duru G, et al. Socio-economic impact of migraine and other episodic headaches in France, Data from the GRIM study. Cephalalgia 2003; 23:703.
16. GRESMI (Groupe de Réflexion sur l'Evaluation de la Sévérité de la Migraine). Study of criteria for evaluating the severity of migraine. Cephalalgia 1999; 19:334.
17. Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman JN, et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 1999; 53:988-94.
18. Lipton RB, Stewart WF. Migraine headaches: epidemiology and comorbidity. Clin Neurosci 1998; 5:2-9.
19. Lucas C, Lanteri-Minet M, Leroy L. The Framig 99 survey III. Therapeutical behaviors of migraineurs. In: Humphrey P, Ferrari M, Olesen J, editors. Frontiers in headache research, Vol. 10, The triptans: novel drugs for migraine. Oxford: Oxford University Press, 2001:305-8.
20. Lantéri-Minet M, Lucas C, Chaffaut C. Comportements thérapeutiques des migraineux, Framig 2000, II. Douleur 2001; 2:233-16.
21. Brennum J, Brinck T, Schriver L, Wanscher B, Soelberg S, Sørensen P, et al. Sumatriptan has no clinically relevant effect in the treatment of episodic tension-type headache. Eur J Neurol 1996; 3:23-8.
22. Lipton RB, Stewart WF, Cady R, Hall C, O'Quinn S, Kuhn T et al. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum study. Headache 2000; 40:782-91.
23. Mathew NT. Transformed migraine, analgesic rebound and other chronic daily headaches. Neurol Clin 1997; 15:167-86.
24. Lipton RB, Stewart WF, Stone AM, Lainez MJ, Sawyer JP. Disability on Strategies of Care Study Group. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: a randomized trial. JAMA 2000; 284:2640-1.
25. Lipton RB, Silberstein SD. The role of headache-related disability in migraine management: implications for headache treatment guidelines. Neurology 2001; 56 (Suppl. 1):S35-S42.